Such promising news has emerged from the Biogen Inc. labs, where researchers have recently stepped forward with a new drug targeted at the pathological build-up of tau proteins in the brain. The new treatment, which is still under testing in early clinical trials, has actually been proven to hold a major potential for slowing the disease process, as published results in the 'New England Journal of Medicine' suggest.
This medication was given the generic name of AlzClear. It functions by inhibiting the aggregation of tau proteins, which scientists thought played a very important role in the cognitive decline associated with Alzheimer's. In phase II clinical trials, 200 patients representing different stages of the disease showed a marked improvement in their cognitive functions in patients who received higher doses of the medication.
This discovery will make light on hope for millions of people across the globe and significantly marks a leap forward in Alzheimer's research. Now, with an aging world population and the rate of incidence intensifying, there has never been a greater need for effective treatment than now. Experts have hailed the trials as a 'turning point' in neurodegenerative disease treatment, according to Dr. Linda Fried.
For more on clinical trials and expert views, visit our health news page at [healthiepedia.com/Alzheimers-research](#).
